Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab-based first-line phase 3 trial in advanced esophageal squamous cell carcinoma
2016-001514-20Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2016
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Esophageal Squamous Cell Carcinoma (ESCC) comparing Nivolumab plus ipilimumab, Nivolumab plus fluorouracil plus cisplatin and Fluorouracil plus cisplatin (3 arms). Primary endpoint: Overall survival in subjects with PD-L1 expressing tumors. Started Oct 2016; status: completed.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on 2016-001514-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001514-20.